Cummins Strategy Partners
Strategic advisors to Pharma and Biotech for EU commercialisation
Who we are
Andrew is a seasoned European commercialisation strategist with deep expertise in helping global biopharma companies bring rare-disease and specialty therapies to market across Europe. With more than 30 years of experience and focus spanning early-access programmes, pricing and reimbursement strategy, real-world evidence generation, rare-disease launch models, and complex cross-border distribution, Andrew has supported numerous companies in accelerating access for patients with high-unmet-need conditions.
He is particularly recognised for his command of Europe’s fragmented early-access frameworks used for rare-disease and specialty products. Andrew blends regulatory fluency with hands-on commercial execution, guiding companies through orphan-drug commercialisation, distributor selection, supply-chain design, and go-to-market strategy tailored specifically for small, often-heterogeneous patient populations.
Andrew’s advisory practice is rooted in providing pragmatic, actionable pathways for Pharma/Biotech entering Europe for the first time , particularly those developing ultra-rare, rare, or highly specialised therapies that require bespoke access, funding, and distribution solutions. His work spans programmes ranging from early-access design and paid-for unlicensed supply to RWE frameworks and full EU launch planning. He is known for simplifying complexity, anticipating obstacles, and delivering clear, commercially sound routes that maximise the probability of patient access across Europe.
Founder & Managing Director
Andrew Cummins
Yalcin is a senior commercial, market-access, and business-development leader with more than two decades of experience operating at the intersection of rare disease, specialty pharmaceuticals, and international expansion. His career has been defined by building credible access pathways for complex therapies, shaping partner strategies that stand up to regulatory and payer scrutiny, and translating global ambition into executable, in-market reality.
Most recently, Yalcin held senior leadership roles at Sciensus, including Vice President, Market Access & Business Development (Emerging Markets) and Director, Global Business Development. In these roles, he was responsible for identifying, structuring, and executing multi-country access and distribution strategies across a diverse range of geographies. His remit extended beyond pure deal-making: he worked closely with manufacturers to pressure-test value propositions, assess real-world feasibility, and design routes to market that aligned regulatory pathways, pricing logic, and operational delivery.
A defining feature of Yalcin’s work has been his ability to bridge strategic intent and operational execution. He has supported biotech and specialty pharma companies navigating early access, distributor selection, and longer-term commercialisation planning, often in markets where infrastructure, reimbursement, and clinical practice vary significantly. This has given him a pragmatic understanding of what actually enables patient access versus what only works on paper.
Yalcin founded and led BioTurk Life Sciences Consultancy, advising life-science companies on commercial strategy, market entry, and partnership development. Earlier in his career, he held senior commercial and services roles across global pharmaceutical organisations including Sanofi Genzyme, Sandoz, Eli Lilly, and Colgate-Palmolive.
